Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
([[) |
(grammar) |
||
| Line 1: | Line 1: | ||
[[File:Fibrates.svg.png|thumb|450px]] | [[File:Fibrates.svg.png|thumb|450px]] | ||
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. | Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. | ||
This fibrate reduces triglyceride and | This fibrate reduces triglyceride and rises HDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_27425/_pdf Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.]</ref> | ||
<gallery> | <gallery> | ||
Revision as of 22:43, 24 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and rises HDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
- ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02
